细胞类型依赖的差异细胞毒性和基因毒性效应:l-抗坏血酸对健康淋巴细胞和HL-60癌细胞的综合机制研究

IF 3.6 3区 医学 Q2 CHEMISTRY, MEDICINAL
Mehmet Tahir Hüsunet, Mehmet Bertan Yilmaz, Hasan Basri İla
{"title":"细胞类型依赖的差异细胞毒性和基因毒性效应:l-抗坏血酸对健康淋巴细胞和HL-60癌细胞的综合机制研究","authors":"Mehmet Tahir Hüsunet,&nbsp;Mehmet Bertan Yilmaz,&nbsp;Hasan Basri İla","doi":"10.1002/ardp.70093","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p><span>l</span>-Ascorbic acid exhibits paradoxical behavior as both antioxidant and pro-oxidant in cancer treatment, with mechanisms and optimal dosing remaining unclear. This in vitro study investigated <span>l</span>-ascorbic acid's effects on healthy lymphocytes and HL-60 leukemia cells using concentrations of 0.5–2 mg/mL for 6 and 24 h. Analyses included cell viability, gene expression, DNA damage, mutagenicity, and oxidative stress markers. The results demonstrated a dose-dependent increase in the metabolic activity of HL-60 cells, with a ~ sixfold increase observed at 2 mg/mL (<i>p</i> ≤ 0.001), and opposing modulation of FAS/catalase gene expression between the two cell types. In healthy lymphocytes, both genes were suppressed with increasing exposure, while HL-60 cells exhibited significant early induction (29-fold for FAS and 47-fold for catalase, <i>p</i> ≤ 0.001). <span>l</span>-Ascorbic acid concentrations (0.5–2 mg/mL) exhibited no significant genotoxicity in healthy cells, increased antioxidant status in healthy lymphocytes, and elevated oxidative stress (a 1.4-fold increase in the oxidative stress index at 24 h, <i>p</i> ≤ 0.001) in HL-60 cells. Ames testing confirmed non-mutagenicity, while plasmid analysis revealed bimodal effects, being pro-oxidant at an intermediate dose and protective at a high dose. These findings suggest that <span>l</span>-ascorbic acid requires cell-type-specific application in hematological malignancies and may offer a therapeutic window in leukemia treatment protocols, providing a foundation for optimizing combination strategies with conventional chemotherapeutics.</p></div>","PeriodicalId":128,"journal":{"name":"Archiv der Pharmazie","volume":"358 9","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cell-Type-Dependent Differential Cytotoxic and Genotoxic Effects: Comprehensive Mechanistic Insights of L-Ascorbic Acid on Healthy Lymphocytes and HL-60 Cancer Cells\",\"authors\":\"Mehmet Tahir Hüsunet,&nbsp;Mehmet Bertan Yilmaz,&nbsp;Hasan Basri İla\",\"doi\":\"10.1002/ardp.70093\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n <p><span>l</span>-Ascorbic acid exhibits paradoxical behavior as both antioxidant and pro-oxidant in cancer treatment, with mechanisms and optimal dosing remaining unclear. This in vitro study investigated <span>l</span>-ascorbic acid's effects on healthy lymphocytes and HL-60 leukemia cells using concentrations of 0.5–2 mg/mL for 6 and 24 h. Analyses included cell viability, gene expression, DNA damage, mutagenicity, and oxidative stress markers. The results demonstrated a dose-dependent increase in the metabolic activity of HL-60 cells, with a ~ sixfold increase observed at 2 mg/mL (<i>p</i> ≤ 0.001), and opposing modulation of FAS/catalase gene expression between the two cell types. In healthy lymphocytes, both genes were suppressed with increasing exposure, while HL-60 cells exhibited significant early induction (29-fold for FAS and 47-fold for catalase, <i>p</i> ≤ 0.001). <span>l</span>-Ascorbic acid concentrations (0.5–2 mg/mL) exhibited no significant genotoxicity in healthy cells, increased antioxidant status in healthy lymphocytes, and elevated oxidative stress (a 1.4-fold increase in the oxidative stress index at 24 h, <i>p</i> ≤ 0.001) in HL-60 cells. Ames testing confirmed non-mutagenicity, while plasmid analysis revealed bimodal effects, being pro-oxidant at an intermediate dose and protective at a high dose. These findings suggest that <span>l</span>-ascorbic acid requires cell-type-specific application in hematological malignancies and may offer a therapeutic window in leukemia treatment protocols, providing a foundation for optimizing combination strategies with conventional chemotherapeutics.</p></div>\",\"PeriodicalId\":128,\"journal\":{\"name\":\"Archiv der Pharmazie\",\"volume\":\"358 9\",\"pages\":\"\"},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2025-09-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Archiv der Pharmazie\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/ardp.70093\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archiv der Pharmazie","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ardp.70093","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

摘要

l-抗坏血酸在癌症治疗中作为抗氧化剂和促氧化剂表现出矛盾的行为,其机制和最佳剂量尚不清楚。本实验研究了l-抗坏血酸对健康淋巴细胞和HL-60白血病细胞在0.5-2 mg/mL浓度下作用6和24 h的影响。分析包括细胞活力、基因表达、DNA损伤、诱变性和氧化应激标志物。结果显示,HL-60细胞的代谢活性呈剂量依赖性增加,当浓度为2 mg/mL时,其代谢活性增加约6倍(p≤0.001),两种细胞类型对FAS/过氧化氢酶基因表达的调节相反。在健康淋巴细胞中,这两个基因都随着暴露的增加而被抑制,而HL-60细胞表现出显著的早期诱导(FAS为29倍,过氧化氢酶为47倍,p≤0.001)。l-抗坏血酸浓度(0.5-2 mg/mL)对健康细胞没有显著的遗传毒性,但会增加健康淋巴细胞的抗氧化状态,并增加HL-60细胞的氧化应激(24 h时氧化应激指数增加1.4倍,p≤0.001)。Ames测试证实了其非诱变性,而质粒分析显示了双峰效应,在中剂量时具有促氧化作用,在高剂量时具有保护作用。这些发现表明,l-抗坏血酸在血液系统恶性肿瘤中需要细胞类型特异性的应用,并可能为白血病治疗方案提供一个治疗窗口,为优化与传统化疗药物的联合策略提供基础。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Cell-Type-Dependent Differential Cytotoxic and Genotoxic Effects: Comprehensive Mechanistic Insights of L-Ascorbic Acid on Healthy Lymphocytes and HL-60 Cancer Cells

Cell-Type-Dependent Differential Cytotoxic and Genotoxic Effects: Comprehensive Mechanistic Insights of L-Ascorbic Acid on Healthy Lymphocytes and HL-60 Cancer Cells

l-Ascorbic acid exhibits paradoxical behavior as both antioxidant and pro-oxidant in cancer treatment, with mechanisms and optimal dosing remaining unclear. This in vitro study investigated l-ascorbic acid's effects on healthy lymphocytes and HL-60 leukemia cells using concentrations of 0.5–2 mg/mL for 6 and 24 h. Analyses included cell viability, gene expression, DNA damage, mutagenicity, and oxidative stress markers. The results demonstrated a dose-dependent increase in the metabolic activity of HL-60 cells, with a ~ sixfold increase observed at 2 mg/mL (p ≤ 0.001), and opposing modulation of FAS/catalase gene expression between the two cell types. In healthy lymphocytes, both genes were suppressed with increasing exposure, while HL-60 cells exhibited significant early induction (29-fold for FAS and 47-fold for catalase, p ≤ 0.001). l-Ascorbic acid concentrations (0.5–2 mg/mL) exhibited no significant genotoxicity in healthy cells, increased antioxidant status in healthy lymphocytes, and elevated oxidative stress (a 1.4-fold increase in the oxidative stress index at 24 h, p ≤ 0.001) in HL-60 cells. Ames testing confirmed non-mutagenicity, while plasmid analysis revealed bimodal effects, being pro-oxidant at an intermediate dose and protective at a high dose. These findings suggest that l-ascorbic acid requires cell-type-specific application in hematological malignancies and may offer a therapeutic window in leukemia treatment protocols, providing a foundation for optimizing combination strategies with conventional chemotherapeutics.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Archiv der Pharmazie
Archiv der Pharmazie 医学-化学综合
CiteScore
7.90
自引率
5.90%
发文量
176
审稿时长
3.0 months
期刊介绍: Archiv der Pharmazie - Chemistry in Life Sciences is an international journal devoted to research and development in all fields of pharmaceutical and medicinal chemistry. Emphasis is put on papers combining synthetic organic chemistry, structural biology, molecular modelling, bioorganic chemistry, natural products chemistry, biochemistry or analytical methods with pharmaceutical or medicinal aspects such as biological activity. The focus of this journal is put on original research papers, but other scientifically valuable contributions (e.g. reviews, minireviews, highlights, symposia contributions, discussions, and essays) are also welcome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信